Detrusin LA - Tolterodine Tartrate | VetSafeCare.Com

Brand

Detrusin LA

Tolterodine Tartrate — UniMed UniHealth
4mg / capsule (extended release) · 2mg / capsule (extended release)

Alternatives

7

Routes

PO

Presentations

2

Generic profile Browse alternatives View combinations

Presentations

Capsule (Extended Release) · 4mg / capsule (extended release)

1 capsule (extended release)

৳15

Capsule (Extended Release) · 2mg / capsule (extended release)

1 capsule (extended release)

৳8

Dose rules

No structured dose rules are linked to this brand yet.

Dose reference

Human

The recommended dose for tolterodine is 2 mg twice daily. In case of troublesome side effects the dose may be reduced from 2 mg to 1 mg twice daily. The recommended total daily dose of tolterodine is 2 mg (1 mg b.i.d.) for patients with impaired renal function, impaired liver function, or receiving concomitant medication with potent CYP3A inhibitors, such as macrolide antibiotics (e.g. erythromycin and clarithromycin) or azole antifungal agents (e.g. ketoconazole, itraconazole and miconazole). After six months the need for further treatment should be considered.

Clinical notes

Applications:

N/A

Indication Notes:
Tolterodine Tartrate is indicated for the treatment of overactive bladder with symptoms of urinary urgency, frequency, and/or urge incontinence.
Avoid In:

N/A

Contraindication Notes:
Tolterodine is contraindicated in those patients with urinary retention, uncontrolled narrow angle glaucoma, known hypersensitivity to tolterodine or any other component of the drug.
Tolterodine is a competitive, specific muscarinic receptor antagonist which exhibits a selectivity for the urinary bladder over salivary glands, which have been demonstrated in non clinical pharmacological in vivo studies. Tolterodine has a high specificity for muscarinic receptors. A major active metabolite (5-hydroxymethyl derivative) of tolterodine exhibits a pharmacological profile which is similar to that of the parent compound. In extensive metabolisers this metabolite contributes significantly to the therapeutic effect of tolterodine. The effect of treatment can be expected within 4 weeks.
Pharmacokinetic interactions are possible with other drugs metabolised by or inhibiting cytochrome P450 2D6 (CYP2D6) or CYP3A4. Concomitant treatment with fluoxetine does not result in a clinically significant interaction.Ketoconazole, a potent inhibitor of CYP3A, significantly increased plasma concentrations of tolterodine when coadministered to poor metabolisers (i.e. persons devoid of CYP2D6 metabolic pathway).Clinical studies have shown no interactions with warfarin or combined oral contraceptives (ethinyloestradiol or levonorgestrel).
Tolterodine may cause mild to moderate antimuscarinic effects, like dryness of mouth, dyspepsia and/or reduced lacrimation.
Overdosage with Tolterodine Tartrate capsules can potentially result in severe central anticholinergic effects and should be treated accordingly. ECG monitoring is recommended in the event of overdosage.
There are no studies in pregnant women. Therefore, tolterodine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Use of tolterodine during lactation should be avoided since no data on excretion of the drug into breast milk in humans is available.
Tolterodine should be used with caution in the following patients: at risk for urinary retention at risk for decreased gastrointestinal motility with impaired renal function with impaired hepatic function Organic reasons for urge and frequency should be considered before treatment.
Pediatric use: Safety and effectiveness of tolterodine in children have not been established.Geriatric use: No overall differences in safety were observed between the older and younger patients treated with Tolterodine.